Astellas gains extensive new territorial rights to Eligard
This article was originally published in Scrip
Executive Summary
Astellas' European subsidiary has acquired from the private US firm Tolmar Holdings a licence to commercialise the prostate cancer drug Eligard (leuprolide acetate) in a broad range of Asian, Middle Eastern, North African and CIS countries.